Parasitic Infections – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Parasitic Infections Market Outlook

Thelansis’s “Parasitic Infections Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Parasitic Infections treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Parasitic Infections Overview

Parasitism, a condition where one organism (the parasite) lives off the host's resources, is akin to other infections, such as bacterial or viral infections. In parasitic interactions, glycan-binding proteins (GBPs) produced by the parasite interact with the host's glycomes, while the parasite's glycans engage with the host's GBPs and antibodies. Parasitic diseases generally fall into two categories: those caused by protists, which are single-celled organisms, and those caused by helminths, which are worms or metazoans. Key protozoan parasites include Plasmodium (responsible for malaria), Entamoeba histolytica (causing amebiasis), Leishmania (causing leishmaniasis), and Trypanosoma (causing sleeping sickness and Chagas disease). Parasitic worms encompass trematodes like Schistosoma mansoni (causing schistosomiasis), nematodes such as Ascaris lumbricoides, and cestodes or tapeworms like Taenia solium (causing taeniasis). Parasites employ various transmission methods to infect hosts, including direct surface contact, active percutaneous entry, oral ingestion, feco-oral transmission, cyclic-alimentary routes (e.g., malaria transmission via Anopheles mosquitoes during feeding), sexual contact, and diaplacental transmission (e.g., fetal toxoplasmosis). The FDA has approved medications like secnidazole, ivermectin, and albendazole for treating various parasitic worm infections.

• In the United States, parasitic infections are common, impacting at least 12 million Americans.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: